Wojciech Baran

Prof. Wojciech Baran

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
LFLaura K. Ferris
Laura K. Ferris
EOElyssa Ott
Elyssa Ott
JJJingzhi Jiang
Jingzhi Jiang
HHH. Chih-Ho Hong
H. Chih-Ho Hong
SLShu Li
Shu Li
WBWojciech Baran
Wojciech Baran
Objectives: Guselkumab, an interleukin-23 antagonist, is approved for self-administration with the UltraSafe Plus™ syringe to treat moderate-to-severe plaque-type psoriasis. We evaluated the efficacy, safety, pharmacokinetics, and acceptability of guselkumab administered using a novel patient-controlled injector (One-Press) in psoriasis patients. Materials and methods: This Phase 3, multicentre, double-blind, placebo-controlled study (ORION, Clinicaltrials.gov identifier-NCT02905331) randomized adults with moderate-to-severe psoriasis (4:1) to guselkumab 100 mg at Weeks 0/4/12/20/28 or placebo at Weeks 0/4/12 with crossover to guselkumab 100 mg at Weeks 16/20/28. Week 16 co-primary endpoints were the proportions of patients achieving Investigator Global Assessment (IGA) cleared/minimal (IGA 0/1) and Psoriasis Area and Severity Index 90% improvement (PASI90) responses. One-Press usability/acceptability was evaluated using the Self-Injection Assessment Questionnaire (SIAQ) and Patient-Controlled Injection Device Questionnaire. Final assessments occurred at Week 40. Results: At Week 16, significantly higher proportions of guselkumab-treated (N = 62) than placebo-treated (N = 16) patients achieved IGA 0/1 (80.6% vs. 0.0%, p < .001) and PASI90 (75.8% vs. 0.0%, p < .001) responses. Adverse events were comparable between treatments. SIAQ results demonstrated 99% (68/69) of patients were satisfied/very satisfied with One-Press at Week 28. Conclusions: Guselkumab administered using the One-Press patient-controlled injector was efficacious and well-tolerated in moderate-to-severe psoriasis patients, consistent with previously reported Phase-3 studies of guselkumab administered using UltraSafe Plus. One-Press was highly acceptable to patients.

24 July 2020 in Disease Markers
Verified
Journal Article
Open access
PDF file
MŻMagdalena Żychowska
Magdalena Żychowska
ABAleksandra Batycka-Baran
Aleksandra Batycka-Baran
WBWojciech Baran
Wojciech Baran
Background. Interleukin-17 is supposed to play an important role in the pathogenesis of oral lichen planus (OLP). However, there is scarce data in the literature on its significance in the cutaneous variant of the disease. Objectives. To determine the serum level and tissue immunoexpression of IL-17 in cutaneous lichen planus (CLP). Methods. Fifty-two adult patients with CLP, without any significant autoimmune or inflammatory conditions, were included in the first part of the study. The control group consisted of 27 age- and sex-matched healthy volunteers. Serum concentration of IL-17 was quantified using enzyme-linked immunosorbent assay (ELISA) kit. In the second part of the study, the tissue expression of IL-17 was assessed in archival paraffin-embedded biopsy specimens from CLP (n=14) against normal control tissues (n=11) using immunohistochemical assays. The expression was evaluated using Zeiss Axio Imager A2 light microscope. Positively stained cells were counted in 10 fields of view for biopsy specimen at 200x magnification, and the mean value was calculated. Results. The serum level of IL-17 was significantly elevated in patients with CLP, compared with healthy volunteers (0.218±0.221 ng/ml versus 0.126±0.058 ng/ml, respectively; p=0.025). No correlation was found between the serum concentration of IL-17 and patient age, gender, disease duration, extent of skin involvement, the presence or intensity of pruritus, and coexistence of mucosal lesions. In tissue samples from CLP lesions, significantly higher numbers of cells expressing IL-17 were found when compared to a healthy skin (p<0.001). Conclusion. Elevated serum concentration of IL-17 and high expression in a lesional skin support the hypothesis that IL-17 is implicated in the immunopathogenesis of CLP. These findings may constitute a premise for the future use of anti-IL-17 monoclonal antibodies in the treatment of severe and recalcitrant forms of CLP.

27 September 2018 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
KKKarolina Kopeć-Pyciarz
Karolina Kopeć-Pyciarz
IMIrena Makulska
Irena Makulska
DZDanuta Zwolińska
Danuta Zwolińska
LLLukasz Laczmanski
Lukasz Laczmanski
WBWojciech Baran
Wojciech Baran
Background. Psoriasis is currently regarded as a chronic systemic inflammatory disease associated with increased cardiovascular risk. Advanced glycation end products (AGEs) contribute to the development of atherosclerosis. Objectives. The aim of the study was the assessment of skin autofluorescence (SAF), as a measure of AGE accumulation, in individuals suffering from chronic plaque psoriasis without any comorbid conditions. Methods. A study group consisted of 70 patients with chronic plaque psoriasis without any comorbid conditions and 59 healthy controls, matched by age and gender. AGE accumulation was assessed by SAF (AGE Reader, DiagnOptics BV) which is a validated and noninvasive technique. Relations between SAF and some clinical and laboratory data were assessed. Results. SAF was positively correlated with age both in patients with psoriasis and controls (R=0.722, p<0.00001 and R=0.613, p<0.00001, respectively). There was significantly increased SAF in patients with psoriasis with elevated levels of C-reactive protein (CRP) and increased erythrocyte sedimentation rate (ESR) compared to controls (p<0.00001; p<0.00001, respectively, after adjustment to age). Increased SAF was found in psoriatic patients with prediabetes (HbA1c 5.7–6.4%) compared to controls (p<0.0012, after adjustment to age). Conclusion. Systemic inflammation (increased CRP level), prediabetes, and aging may influence enhanced AGE accumulation in patients with psoriasis without any comorbidities. SAF may be considered as a useful, noninvasive method to identify patients with psoriasis at increased cardiovascular risk.

15 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAleksandra Batycka-Baran
Aleksandra Batycka-Baran
ŁMŁukasz Matusiak
Łukasz Matusiak
DNDanuta Nowicka-Suszko
Danuta Nowicka-Suszko
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
WBWojciech Baran
Wojciech Baran
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Recently, some S100 proteins have been suggested to play an important role in the pathogenesis of chronic immune-mediated inflammatory diseases and they may constitute valuable biomarkers for these diseases’ diagnosis and monitoring. The objective of the current study was to investigate, for the first time, serum levels of S100A4 and S100A15 in individuals suffering from HS. Furthermore, we assessed the associations between S100A4 and S100A15 serum levels and the severity of disease, CRP serum concentration and some demographic and clinical data. Serum levels of S100A4 and S100A15 were evaluated with the commercially available ELISA kit according to the manufacturer’s instructions. The serum level of S100A4 in individuals with HS was significantly elevated as compared to controls, with the highest level found in the individuals in Hurley stage II. The S100A15 serum level was positively correlated with the CRP concentration and was associated with the severity of the disease. The serum level of S100A15 in the individuals in Hurley stage III was significantly elevated compared to that of the controls and the individuals with HS in Hurley stages I and II. S100A4 and S100A15 may be considered as new serum biomarkers for the monitoring of HS progression, and they may play a role in the pathogenesis of HS by promoting inflammatory process and fibrosis.

18 November 2020 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
JPJ Putek
J Putek
TPT Przybyla
T Przybyla
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
WBWojciech Baran
Wojciech Baran
ABA Batycka-Baran
A Batycka-Baran
Gel nail polish is commonly used in manicures; how­ever, research into the side-effects of gel nail...

14 July 2022 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
BPBartosz Ptak
Bartosz Ptak
EKEmilia Knosala
Emilia Knosala
GWGrażyna Wąsik
Grażyna Wąsik
RBRafał Białynicki-Birula
Rafał Białynicki-Birula
WBWojciech Baran
Wojciech Baran
ABAleksandra Batycka-Baran
Aleksandra Batycka-Baran
Linear IgA bullous dermatosis (LABD) is a rare, acquired autoimmune disease which is characterized by itchy, clustered, subepidermal bullae with linear IgA deposits at the dermo-epidermal junction in direct immunofluorescence assay (DIF). In 1979, Chorzelski and Jab³oñska distinguished LABD as a...